vedolizumab   

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vedolizumab

References
1. Ponath PD, Ringler DJ, ST, Newman W, Saldanha J, Bendig MM. (2006)
Humanized immunoglobulin reactive with α4β7 integrin.
Patent number: US7147851 B1. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 15/08/1996. Publication date: 12/12/2006.
2. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. (2009)
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
J. Pharmacol. Exp. Ther., 330 (3): 864-75. [PMID:19509315]